Specialist disease areas firm Sobi is reported to have agreed a deal with NHS England for NHS provision of Ravicti, a drug for controlling the effects of urea-cycle disorders. This follows approval last week from the Scottish Medicines Consortium (SMC) for its provision in Scotland. NHS England has not commented publicly.
Ravicti differs from currently used drugs in that it is a palatable liquid formulation, as opposed to a large number of pills with unpleasant taste.
This is a valuable reminder that the patient impact of medicines is a factor that will be considered during the approvals process. The easier administration of this formulation (especially for children), along with eliminating the need to remember large numbers of pills, offers improved patient experience, better adherence to the regimen, and reduced (costly) hospital admissions from adverse events.